
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is a promising company, with a diverse product portfolio that caters to the diagnosis and treatment of various diseases, including cancer. Their recent acquisition of LNTH-2501 and the FDA's positive signal on its safety and efficacy bodes well for potential future approval and revenue generation. Additionally, their royalty opportunities, partnerships, and a solid 2027 forecast make the stock undervalued compared to its peers. The management team's efforts to find a permanent CEO and a focused approach to rolling out its new product, PYL TruVu, set the stage for potential growth.
Bears say
Lantheus Holdings is facing challenges in maintaining market share and profitability due to a dynamic reimbursement landscape and increased competition in the radiopharmaceutical industry. Their recent earnings call highlighted the need to de-risk their 2026 forecast with a conservative outlook and potential risks such as pricing pressures and delays in securing FDA approvals for new products. The company's recent leadership changes and CEO transition may also lead to operational and execution challenges. These factors contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares